These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 30552023)

  • 21. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
    Kaplanov I; Carmi Y; Kornetsky R; Shemesh A; Shurin GV; Shurin MR; Dinarello CA; Voronov E; Apte RN
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1361-1369. PubMed ID: 30545915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κB activation in a short-term monocyte-derived dendritic cell culture promoting 'FAST' regulatory dendritic cells.
    Rojas-Canales D; Krishnan R; Jessup CF; Coates PT
    Clin Exp Immunol; 2012 Mar; 167(3):447-58. PubMed ID: 22288588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.
    Pan K; Lv L; Zheng HX; Zhao JJ; Pan QZ; Li JJ; Weng DS; Wang DD; Jiang SS; Chang AE; Li Q; Xia JC
    Immunol Cell Biol; 2014 Mar; 92(3):263-74. PubMed ID: 24296809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The deubiquitinase OTUB1 augments NF-κB-dependent immune responses in dendritic cells in infection and inflammation by stabilizing UBC13.
    Mulas F; Wang X; Song S; Nishanth G; Yi W; Brunn A; Larsen PK; Isermann B; Kalinke U; Barragan A; Naumann M; Deckert M; Schlüter D
    Cell Mol Immunol; 2021 Jun; 18(6):1512-1527. PubMed ID: 32024978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
    Shi LZ; Fu T; Guan B; Chen J; Blando JM; Allison JP; Xiong L; Subudhi SK; Gao J; Sharma P
    Nat Commun; 2016 Aug; 7():12335. PubMed ID: 27498556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.
    Kim YJ; Park SJ; Broxmeyer HE
    J Immunol; 2011 Sep; 187(5):2291-301. PubMed ID: 21795591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo.
    Soares H; Waechter H; Glaichenhaus N; Mougneau E; Yagita H; Mizenina O; Dudziak D; Nussenzweig MC; Steinman RM
    J Exp Med; 2007 May; 204(5):1095-106. PubMed ID: 17438065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.
    Li F; Yang Z; Savage TM; Vincent RL; de Los Santos-Alexis K; Ahn A; Rouanne M; Mariuzza DL; Danino T; Arpaia N
    Sci Immunol; 2024 Oct; 9(100):eadn9879. PubMed ID: 39423284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors.
    Scheuerpflug A; Ahmetlić F; Bauer V; Riedel T; Röcken M; Mocikat R
    Cancer Immunol Immunother; 2021 May; 70(5):1343-1350. PubMed ID: 33141285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
    Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.